2009 ANNUAL REPORT About PAREXEL PAREXEL International, a leading global biopharmaceutical services organization, has been a proven, committed partner to pharmaceutical, biotechnology, and medical device companies for the past 27 years. Together with our customers, we have combined our experience, expertise, and innovative insights in a shared mission to help prevent and cure disease and bring signifi cant life-saving treatments to patients worldwide. For more than two decades, PAREXEL has been at the forefront of designing effective partnership models, providing the perfect complement of clinical development expertise, leading technologies, and global access to our customers in order to meet their evolving needs. In this regard, PAREXEL has received multiple awards honoring the Company’s performance, including the biopharmaceutical industry’s Scrip Award for Best Contract Research Organization in December 2008, which recognized PAREXEL’s consistent achievements in exceeding customer expectations, as well as the Company’s broad range of services, its truly global nature, and the positive impact it has had on advancing healthcare worldwide. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has approximately 9,300 employees. Financial Highlights FISCAL YEAR ENDED JUNE 30 2009 2008 2007 (In Thousands Except Per Share Data) Total Service Revenue $ 1,050,755 $ 964,283 $ 741,955 Clinical Research Services $ 804,237 $ 745,641 $ 548,838 Perceptive Informatics, Inc. $ 124,733 $ 88,838 $ 72,481 PAREXEL Consulting and Medical Communications Services $ 121,785 $ 129,804 $ 120,636 Income from Operations $ 75,644* $ 86,666 $ 57,566 Net Income $ 39,307* $ 64,640 $ 37,289 Diluted Earnings Per Share $ 0.68* $ 1.12 $ 0.66 Working Capital $ 191,705 $ 146,535 $ 118,746 Total Assets $ 1,224,461 $ 948,870 $ 680,013 Stockholders’ Equity $ 414,745 $ 428,091 $ 316,616 * Includes a $15 million reserve for wind-down costs and bad debt expense related to a client’s default on a contract, and net income and diluted earnings per share also include a related $7.1 million tax benefi t. Fiscal 2009 Segment Information Fiscal 2009 Geographic Revenue Fiscal Year End Backlog (Dollars in Millions) (Dollars in Millions) (Dollars in Millions) 40.6% $2,176 $426.3 $2,059 Americas 76.5% $1,507 $804.2 50.3% Clinical 11.9% $528.9 Research $124.7 Services Perceptive Informatics Europe/ Middle East/ 11.6% Africa $121.8 9.1% $95.6 PAREXEL 2007 2008 2009 Consulting and Asia/Pacific Medical Communications Services The Face of Partnership PAREXEL’s skilled approach to partnering focuses on helping biopharmaceutical companies reduce fi xed costs, shorten development timelines, and speed delivery of safe and effective treatments to market. As the biopharmaceutical industry evolves to meet the perfect complement to customer organizations. PAREXEL demands of a changing global marketplace, companies offers a tremendous breadth and depth of required expertise, of all sizes are embracing new approaches to strategic whether it involves a particular therapeutic area, regulatory partnerships to help increase effi ciency, accelerate time to strategy, or an approach to market access, to bring greater market, reduce costs, and expand their reach into markets innovation and effi ciency to the development process. around the world. These new approaches rely on integrated, long-term relationships with a small number of key partners Evolving strategic partnerships in the biopharmaceutical to create a strategic, cost-effective blend of internal and industry have generated new operating models and have external resources. driven the creation of best practices. We draw on proven processes, verifi able metrics, robust governance, mutual As an innovator in defi ning partnerships in our industry for accountability, and a commitment to continuous improvement. over two decades, PAREXEL utilizes a spectrum of The objectives of PAREXEL’s strategic partnerships with relationship models to meet the diverse requirements of biopharmaceutical companies are clear—to leverage our our customers. We have developed effective long-term dedication, expertise, and innovation, as well as our global strategic relationships, which are characterized by fl exibility reach, to help our partners accelerate completion of key and a deep sense of accountability, to maximize the value of milestones, increase effi ciency, and reduce costs. All of this the relationship for each partner. is aligned with our shared goals to address unmet medical needs and improve healthcare worldwide. By partnering with PAREXEL experts and harnessing the breadth and depth of our capabilities, our customers are On the cover: Representing PAREXEL and one of the faces of partnership is Christopher Erickson, Senior Portfolio Director, able to focus on the discovery of innovative compounds. Clinical Research Services. Throughout all of our partnerships, PAREXEL helps biopharmaceutical executives address key time and cost challenges through more effective outsourcing, while achieving more effi cient development and commercialization of important new treatments. A key element of the success of our strategic partnerships is our ability to provide the 1 PRXL 2009 ANNUAL REPORT To Our Shareholders, Fiscal Year 2009 – a year of worldwide economic turmoil – biopharmaceutical company segment. Leveraging our was challenging for PAREXEL and for the biopharmaceutical clinical development expertise, leading eClinical technologies, industry, yet our business weathered the storm quite well. We and global access, PAREXEL was also able to develop entered the fi scal year with strong new business momentum signifi cant strategic partnerships with a number of top biophar- and record backlog, completed the acquisition of ClinPhone, maceutical companies. Additionally, although the global crisis and grew total service revenue in an environment of slowing in the capital and credit markets made it more diffi cult for many client demand. At the same time, tight cost controls and small biopharmaceutical companies to secure funding for aggressive pursuit of operating effi ciencies enabled us to their clinical development trials this past year, there are now deliver another profi table year. promising signs that sources of funding are starting to fl ow again into this client segment. A key objective in Fiscal Year 2009 was to continue to harvest the growth and profi tability potential of the global With our worldwide infrastructure demonstrating its value as a clinical infrastructure that we have built over the past two driver of top-line growth, Fiscal Year 2009 was a year of strategic decades. Despite an overall decline in biopharmaceutical investment aimed at realizing maximum profi tability from our research and development spending, the dedication and global assets over the long term. Our vision, in this regard, is perseverance of our employees around the world largely to continue to build robust operational processes and information enabled PAREXEL to achieve this goal. We crossed the billion systems that enable us to seamlessly allocate our work, where dollar mark for the fi rst time, growing consolidated service appropriate, to any low-cost location in the world. revenue by 9 percent from last year (11.5 percent on a same store, constant currency basis) to nearly $1.1 billion. Demonstrating the worldwide scope of our business, more With our worldwide infrastructure demonstrating its value than 64 percent of our revenue was generated in locations as a driver of top-line growth, Fiscal Year 2009 was a outside of the United States – the highest percentage of year of strategic investment aimed at realizing maximum any publicly-traded company in the contract research profi tability from our global assets over the long term. services sector. Given the resilience of our business in a diffi cult economy, the Achieving this vision will further improve our operating margins, unanticipated accounting changes related to ClinPhone in the while also enhancing the around-the-clock client support fourth quarter were a signifi cant disappointment in the fi scal aspects of our business as biopharmaceutical R&D becomes year. These changes adversely affected operating margin and more global. It will also serve to further differentiate PAREXEL earnings in the near term, but had no impact on cash or from our competitors. cash fl ow, and thus, will not impair our ability to invest in the business or reduce our net debt. Most importantly, ClinPhone With a direct link to the Company’s vision, investments by our has provided us with the strategic and competitive advantages Clinical Research Services (CRS) business unit have centered we expected, positioning our Perceptive Informatics business on a multi-year, client-focused process redesign called segment as one of the world’s leading eClinical solution “Leveraging Expertise and Process,” or LEAP. In Fiscal Year providers. While the ClinPhone accounting changes reduced 2009, we shifted signifi cant portions of our workfl ow in areas our margins as reported on a GAAP basis, PAREXEL’s non- such as accounting, data management, medical imaging and GAAP operating margin, adjusted for these changes and the software development to a variety of locations in India, South bankruptcy of a small biopharma client, improved nicely from Africa and Eastern Europe, as well as to China and other countries the prior year. We also closed Fiscal Year 2009 with record in Asia. With the implementation of LEAP, processes